Trial Profile
An Open Label Multicenter Phase Ib/II Trial to Determine the Dose of BI 836826 in Combination With Gemcitabine and Oxaliplatin (GemOx) and the Efficacy of BI 836826-GemOx Versus Rituximab (R)- GemOx (R-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Are Not Eligible for, or Have Relapsed/Progressed After Autologous/Allogeneic Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs BI 836826 (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Feb 2021 Results published in the Investigational New Drugs
- 08 May 2018 Status changed from active, no longer recruiting to completed.
- 02 Mar 2018 Status changed from recruiting to active, no longer recruiting.